Health-related quality of life in depression: A STAR*D report

Department of Psychiatry, University of Texas Southwestern Medical School at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75390-9119, USA.
Annals of Clinical Psychiatry (Impact Factor: 2.36). 02/2010; 22(1):43-55.
Source: PubMed


Although major depressive disorder (MDD) is associated with significant impairments in health-related quality of life (HRQOL), few studies have evaluated HRQOL dysfunction in multiple domains. This report examined the psychological, physical, and social domains in a large sample of outpatients who entered the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.
The relationship of HRQOL and baseline sociodemographic and clinical features, including depressive severity, was evaluated. We assessed HRQOL with the 12-item Short Form Health Survey, the 5-item Work and Social Adjustment Scale, and the 16-item Quality of Life Enjoyment and Satisfaction Questionnaire.
Among 2307 participants, greater depressive symptom severity was associated with poorer HRQOL. After controlling for age and depression severity, lower HRQOL was related independently to being African American or Hispanic, less educated, unemployed, divorced or separated, having public medical insurance, and to having more general medical disorders. We found impairments across all 3 domains, with low correlations between the 3 measures of HRQOL chosen, suggesting that they evaluate different and nonoverlapping aspects of function.
Sociodemographically disadvantaged patients with greater general medical and depressive illness burden are at greatest risk for poorer quality of life. Distinct impairments are seen in the 3 domains of HRQOL.

Download full-text


Available from: David W Morris,
  • Source
    • "Participants with a shorter DUD were more frequently younger, unemployed and physically ill: this might have led to a better recognition of depression (Cepoiu et al., 2008; Menchetti et al., 2009), and to earlier treatment, thus shortening the DUD. However it is unlikely these factors were entirely responsible for the effect of the DUD on clinical outcomes since they were accounted for in the analyses and, except younger age, they impact negatively on antidepressant response and disability (Bagby et al., 2002; Daly et al., 2010). Changes in disability were largely, albeit not entirely, explained by changes in depressive symptoms. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The duration of untreated depression (DUD) might have a substantial impact on the clinical outcomes; however, there are important knowledge gaps including the effects on disability and potential differences between first-episode and recurrent episodes of depression. We recruited 121 outpatients with first episode and recurrent major depression, and conducted prospective clinical assessments over six months. Clinical outcomes included response to antidepressant therapy, remission and changes in disability. Patients with a DUD of six months or shorter were more frequently young, unemployed and had higher levels of physical illnesses than those with a longer DUD (all p<0.05). A shorter DUD was associated with significantly higher odds of response at 12 weeks (adjusted odds ratio 2.8; 95% CI: 1.2-6.8) and remission at 24 weeks (4.1; 95% CI: 1.6-10.5) after adjusting for relevant confounders. Changes in disability ratings were analyzed with growth curve analysis and showed steeper declines among those with a shorter DUD. The associations of DUD on clinical outcomes were evident both in patients with first-episode and recurrent depression. Naturalistic design. Self-rated assessment of disability. Findings from subgroup analyses should be replicated in larger sample size. A shorter duration of untreated depression is associated with more favorable outcomes for major depression, including depression-related disability. This association seems to work both at the first and recurrent episodes, which might have direct implications for both primary and secondary prevention. Copyright © 2015 Elsevier B.V. All rights reserved.
    Journal of Affective Disorders 01/2015; 175C:224-228. DOI:10.1016/j.jad.2015.01.014 · 3.38 Impact Factor
  • Source
    • "h are in accordance with our findings . It can be said that participating in higher education can contribute to increased awareness and knowledge , and consequently enhance QOL skills , enjoying a healthy and happy life . Depression is a significant predictor of poor QOL . Results of some studies indicate that chronic diseases such as depression ( Daly et al . 2010 ) , diabetes ( Porojan et al . 2012 ) , cancer ( Johansson et al . 2008 ) , etc . affect various aspects of patients ' QOL . Poor health - related QOL in patients with depression , and those with a prior history of depression , is directly correlated with a mood disorder in this group of patients ( McCall et al . 1999 ; Demyttenaere et "
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Quality of life, one of the major concerns of health professionals, is the main indicator for measuring health status. The present study aimed to assess the quality of life and its predictors in women of reproductive age in Tabriz (Iran). Methods & Materials This cross-sectional study was conducted on 532 married women of reproductive age using a two-stage cluster random sampling method. A self-administered questionnaire was used for data collection. It included questions on demographic characteristics, quality of life (SF-36), female sexual function index (FSFI), and ENRICH marital satisfaction. The general linear model in SPSS-13 was used to determine the predictors of quality of life. Results The mean (standard deviation, SD) score of physical and mental health was 62.2 (17.1) and 60.3 (18.5), respectively (from an attainable score range of 0-100). The highest mean (SD) score [69.5 (25.7)] was obtained for “physical functioning,” while the lowest [52.9 (24.4)] was for “role limitations due to emotional problems.” There was a significant positive correlation between the quality of life and its sub-domains with sexual function (r = 0.15-0.33) and marital satisfaction (r = 0.15 to 0.49). Higher sexual function and marital satisfaction, higher educational level, and no prior history of depression were predictors of physical and mental components of health-related quality of life. Conclusion Physical and mental components of quality of life among women were moderate. Relieving sexual problems and dysfunction and improving marital satisfaction may improve women's quality of life and help to achieve a strong family life.
    Applied Research in Quality of Life 01/2015; DOI:10.1007/s11482-015-9392-0 · 0.82 Impact Factor
  • Source
    • "Major depressive disorder (MDD) is a chronic and debilitating disorder with high rates of medical and psychiatric comorbidity, functional impairment, and significant personal and societal costs (Greenberg et al., 2003; Egede, 2007; Katon et al., 2007; Daly et al., 2010). The heterogeneous symptoms of MDD include sad mood, loss of interest, sleep disturbance, change in appetite, lack of energy, difficulty concentrating, and psychomotor agitation (American Psychiatric Association, 2000). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Vilazodone is a potent selective serotonin reuptake inhibitor and serotonin 1A receptor partial agonist approved for the treatment of major depressive disorder in adults. To assess the efficacy of vilazodone across a range of symptoms and severities of depression, data from two phase III, 8-week, randomized, double-blind, placebo-controlled trials were pooled for analysis. Overall improvement in depressive symptoms measured using the Montgomery-Åsberg Depression Rating Scale (MADRS) and the 17-item Hamilton Depression Rating Scale was statistically significant (P<0.05) for vilazodone treatment compared with placebo as early as Week 1 and continued throughout double-blind treatment. Vilazodone treatment compared with placebo showed significant improvement on all 10 individual MADRS symptom items at end of treatment (P<0.01). Rates of response and remission were significantly greater in the vilazodone group relative to the placebo group, with numbers needed to treat ranging from eight to nine for response and 12-17 for remission. Between-group treatment differences in MADRS and the other outcome measures were similar among all depression subgroups, with no consistent pattern associated with depression severity. These findings support the efficacy of vilazodone across a broad range of depressive symptoms and severities for the treatment of major depressive disorder.
    International clinical psychopharmacology 11/2013; 29(2). DOI:10.1097/YIC.0000000000000016 · 2.46 Impact Factor
Show more